Galmed Pharmaceuticals Ltd (GLMD) was Resumed by ROTH Capital to “Buy” and the brokerage firm has set the Price Target at $6. ROTH Capital advised their investors in a research report released on Jul 6, 2016.
Galmed Pharmaceuticals Ltd closed down -0.06 points or -1.34% at $4.43 with 29,700 shares getting traded on Friday. Post opening the session at $4.49, the shares hit an intraday low of $4.34 and an intraday high of $4.75 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate or FABAC called aramchol. Its product candidate aramchol has the potential to be a disease modifying treatment for fatty liver disorders including Non-Alcoholic Steato-hepatitis (NASH) which constitutes an unmet medical need. The Company has completed three clinical trials of aramchol. The Company focuses on providing a multi-center double-blind randomized Phase IIb placebo-controlled clinical trial of aramchol in NASH patients who also suffer from obesity and insulin resistance. The Company is engaged in developing aramchol for the treatment of NASH in patients who also suffer from obesity and insulin resistance.